Avalyn Pharma Inc. (AVLN) — Current Report

Key Insights

• Avalyn Pharma completed its initial public offering (IPO) with the filing of an Amended and Restated Certificate of Incorporation, marking the company's transition to a public company with shares trading on Nasdaq under ticker AVLN.
• The company authorized a substantial capital structure with 700 million total shares (500 million voting and 200 million non-voting common stock) plus 10 million undesignated preferred shares, providing significant flexibility for future financing and strategic transactions.
• The updated governance documents establish standard public company procedures including stockholder meeting protocols, advance notice requirements for director nominations, and board nomination procedures, reflecting the company's transition from private to public status.
• As an emerging growth company, Avalyn Pharma has elected to use the extended transition period for new accounting standards, which allows more time to comply with accounting rule changes applicable to larger filers.